PhytoHealth was approved by the Industrial Bureau of Ministry of Economic Affairs to be the first bio-pharmaceutical company qualified for the investment incentives specified in the “Bio-Pharmaceutical Industry Development Bylaw”. Consequently, institutional investors of PhytoHealth will enjoy a tax credit equals to 20% of their investment amount; PhytoHealth will also be entitled to receive 35% tax credit on R&D and staff training expenditures.

 

PhytoHealth currently has 8 new drug candidates under development, 6 of them in post-IND clinical trials. PG2, PDC-748, and PH3, the most advanced in process, are in phase 2 clinical trial approved by US FDA.